Anatomy and Cell Biology

Korean Association of Anatomists (대한해부학회)
권호 표지
DOI QR코드

DOI QR Code

Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction

  • Jeon, Po-Sung (Department of Physical Medicine and Rehabilitation, Dong-Eui Medical Center) ;
  • Yang, Sung-Jun (Department of Anatomy, College of Medicine, Kosin University) ;
  • Jeong, Ho-Joong (Department of Physical Medicine and Rehabilitation Anatomy, College of Medicine, Kosin University) ;
  • Kim, Hyun (Department of Anatomy, College of Medicine, Kosin University)
  • Published : 2011.06.30
⟨ Previous Next ⟩

Abstract

Cannabinoids have been proposed to possess neuroprotective properties; though their mechanism of action remains contentious, they are posited to prevent neurodegenerative disorders, including Parkinson's disease, the pathogenesis of which has not been established. Recent studies have demonstrated that induction of proteasomal dysfunction in animal models results in a phenotype similar to Parkinson's disease. Here, we investigated the neuroprotective function of a synthetic cannabinoid-receptor agonist (WIN55.212.2) in dopaminergic neuronal death induced by a proteasomal synthase inhibitor (PSI), additionally testing the hypothesis that WIN55.212.2 modulates cytoplasmic accumulation of parkin and ${\alpha}$-synuclein, a key feature of proteasomal dysfunction in Parkinson's. WIN55.212.2 protects PC12 cells from PSI-induced cytotoxicity, concomitantly inhibiting PSI-induced polyADP ribose polymerase expression and activation of caspase-3. While PSI induces cytoplasmic accumulation of ${\alpha}$-synuclein and parkin, WIN55.212.2 counters these effects. Interestingly, however, while PSI induces the activation and nuclear translocalization of nuclear factor ${\kappa}B$, WIN55.212.2 potentiates this effect. These data are suggestive that WIN55.212.2 might confer a neuroprotective benefit in PSI-induced proteasomal dysfunction, and could further protect against neuronal degeneration stemming from cytoplasmic accumulation of ${\alpha}$-synuclein and parkin. These results indicate that WIN55.212.2 may be a candidate for treatment of neurodegenerative diseases, including Parkinson's disease.

Keywords

References

  1. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999;58:315-48. https://doi.org/10.1016/S0301-0082(98)00087-2
  2. Howlett AC. Efficacy in CB1 receptor-mediated signal transduction. Br J Pharmacol 2004;142:1209-18. https://doi.org/10.1038/sj.bjp.0705881
  3. Mechoulam R, Hanus L, Fride E. Towards cannabinoid drugs: revisited. Prog Med Chem 1998;35:199-243.
  4. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-101.
  5. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006;27:1-4. https://doi.org/10.1016/j.tips.2005.11.003
  6. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006;1071:10-23. https://doi.org/10.1016/j.brainres.2005.11.035
  7. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329-32. https://doi.org/10.1126/science.1115740
  8. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47 Suppl 1:345-58. https://doi.org/10.1016/j.neuropharm.2004.07.030
  9. Mechoulam R, Spatz M, Shohami E. Endocannabinoids and neuroprotection. Sci STKE 2002;2002:re5.
  10. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K, Greenberg DA. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999;19:2987-95.
  11. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di Marzo V, Behl C, Lutz B. CB1 cannabinoid receptors and ondemand defense against excitotoxicity. Science 2003;302:84-8. https://doi.org/10.1126/science.1088208
  12. Sagredo O, Garcia-Arencibia M, de Lago E, Finetti S, Decio A, Fernandez-Ruiz J. Cannabinoids and neuroprotection in basal ganglia disorders. Mol Neurobiol 2007;36:82-91. https://doi.org/10.1007/s12035-007-0004-3
  13. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005;25:1904-13. https://doi.org/10.1523/JNEUROSCI.4540-04.2005
  14. Pryce G, Giovannoni G, Baker D. Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice. Neurosci Lett 2003;341:164-6. https://doi.org/10.1016/S0304-3940(03)00159-9
  15. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007;150:519-25.
  16. Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, Klein T, Fernandez F, Tan J, Shytle RD. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2005;2:29. https://doi.org/10.1186/1742-2094-2-29
  17. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-62. https://doi.org/10.1002/ana.20186
  18. Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 2003;17:790-9. https://doi.org/10.1096/fj.02-0654rev
  19. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001;70:503-33. https://doi.org/10.1146/annurev.biochem.70.1.503
  20. Colell A, Garcia-Ruiz C, Roman J, Ballesta A, Fernandez-Checa JC. Ganglioside GD3 enhances apoptosis by suppressing the nuclear factor-kappa B-dependent survival pathway. FASEB J 2001;15:1068-70. https://doi.org/10.1096/fj.00-0574fje
  21. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 2003;179:38-46. https://doi.org/10.1006/exnr.2002.8050
  22. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-53. https://doi.org/10.1038/nature737
  23. Magnani M, Crinelli R, Bianchi M, Antonelli A. The ubiquitindependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr Drug Targets 2000;1:387-99. https://doi.org/10.2174/1389450003349056
  24. Zhang L, Chang M, Li H, Hou S, Zhang Y, Hu Y, Han W, Hu L. Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res 2007;1153:196-203. https://doi.org/10.1016/j.brainres.2007.03.073
  25. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell 1996;87:13-20. https://doi.org/10.1016/S0092-8674(00)81318-5
  26. Juttler E, Potrovita I, Tarabin V, Prinz S, Dong-Si T, Fink G, Schwaninger M. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). Neuropharmacology 2004;47:580-92. https://doi.org/10.1016/j.neuropharm.2004.05.009
  27. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211. https://doi.org/10.1016/S0197-4580(02)00065-9
  28. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003;53 Suppl 3:S61-S70. https://doi.org/10.1002/ana.10489
  29. Marshansky V, Wang X, Bertrand R, Luo H, Duguid W, Chinnadurai G, Kanaan N, Vu MD, Wu J. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001;166:3130-42. https://doi.org/10.4049/jimmunol.166.5.3130
  30. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology 2006;66(10 Suppl 4):S24-S36. https://doi.org/10.1212/WNL.66.10_suppl_4.S24
  31. Yang SJ, Kim MJ, Jeong HJ, Kim GC, Gil YG, Kim KR, Kim H. Effects of hypoxia on the ubiquitin-proteasome system in primary cortical neuronal cell cultures. Korean J Phys Anthropol 2008;21:21-9. https://doi.org/10.11637/kjpa.2008.21.1.21
  32. Chan GC, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of delta9-tetrahydrocannabinol. J Neurosci 1998;18:5322-32.
  33. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001;413:527-31. https://doi.org/10.1038/35097089
  34. van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabaininduced in vivo excitotoxicity. J Neurosci 2001;21:6475-9.
  35. Abood ME, Rizvi G, Sallapudi N, McAllister SD. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 2001;309:197-201. https://doi.org/10.1016/S0304-3940(01)02065-1
  36. Jeong HJ, Kim SJ, Moon PD, Kim NH, Kim JS, Park RK, Kim MS, Park BR, Jeong S, Um JY, Kim HM, Hong SH. Antiapoptotic mechanism of cannabinoid receptor 2 agonist on cisplatininduced apoptosis in the HEI-OC1 auditory cell line. J Neurosci Res 2007;85:896-905. https://doi.org/10.1002/jnr.21168
  37. Downer EJ, Gowran A, Campbell VA. A comparison of the apoptotic effect of delta(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res 2007;1175:39-47. https://doi.org/10.1016/j.brainres.2007.07.076
  38. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knockout mice. J Neurosci 2002;22:9771-5.
  39. Papa SM. The cannabinoid system in Parkinson's disease: multiple targets to motor effects. Exp Neurol 2008;211:334-8. https://doi.org/10.1016/j.expneurol.2008.03.009
  40. Geng H, Wittwer T, Dittrich-Breiholz O, Kracht M, Schmitz ML. Phosphorylation of NF-kappaB p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination. EMBO Rep 2009;10:381-6. https://doi.org/10.1038/embor.2009.10
  41. Do Y, McKallip RJ, Nagarkatti M, Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 2004;173:2373-82. https://doi.org/10.4049/jimmunol.173.4.2373

Cited by

  1. Endocannabinoid Modulation of Dopaminergic Motor Circuits vol.3, pp.None, 2011, https://doi.org/10.3389/fphar.2012.00110
  2. Nigrostriatal damage after systemic rotenone and/or lipopolysaccharide and the effect of cannabis vol.23, pp.5, 2011, https://doi.org/10.1007/s00580-013-1788-3
  3. Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson’s Disease: A Perspective on Associated Therapeutic Interventions vol.21, pp.17, 2011, https://doi.org/10.3390/ijms21176235